

**IN THE CLAIMS**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

1. (previously presented) An isolated and purified compound that is a heptasaccharide of formula GalNAc- $\alpha$ 1,4-GalNAc- $\alpha$ 1,4-[Glc- $\beta$ 1,3]GalNAc- $\alpha$ 1,4-GalNAc- $\alpha$ 1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose linked to one amino acid or an oligopeptide.

2. (canceled)

3. (previously presented) The compound as defined in claim 1, wherein said one amino acid is asparagine.

4. (previously presented) The compound as defined in claim 1 obtained from a glycoprotein that is isolated and purified from a bacterium selected from *Campylobacter jejuni* and *Campylobacter coli*.

5. (canceled)

6. (currently amended) A method of detecting the compound of claim 1 in a sample ~~a glycan moiety of a bacterial glycoprotein~~, the method comprising subjecting said sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy.

7. (previously presented) A pharmaceutical composition comprising the compound as defined in claim 1 and a physiologically acceptable carrier.

Claims 8-40. (canceled)

41. (previously presented) An isolated and purified heptasaccharide of formula GalNAc- $\alpha$ 1,4-GalNAc- $\alpha$ 1,4-[Glc- $\beta$ 1,3]GalNAc- $\alpha$ 1,4-GalNAc- $\alpha$ 1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose.

42. (previously presented) An immunogenic conjugate comprising the isolated and purified heptasaccharide of claim 41.

43. (previously presented) The isolated and purified heptasaccharide as defined in claim 41 obtained from a glycoprotein that is isolated and purified from *Campylobacter jejuni* or *Campylobacter coli*.

44. (previously presented) A pharmaceutical composition comprising the isolated and purified heptasaccharide of claim 41 and a physiologically acceptable carrier.

45. (previously presented) A pharmaceutical composition comprising the immunogenic conjugate as defined in claim 42 and a physiologically acceptable carrier.

46. (previously presented) The pharmaceutical composition as defined in claim 45, further comprising an immunostimulant.

47. (previously presented) An immunogenic conjugate comprising the compound of claim 1.

48. (previously presented) A pharmaceutical composition comprising the immunogenic conjugate as defined in claim 47 and a physiologically acceptable carrier.

49. (previously presented) The pharmaceutical composition as defined in claim 48 further comprising an immunostimulant.

50. (previously presented) The compound as defined in claim 1, wherein the heptasaccharide is linked to one amino acid.

51. (new) A method of detecting the compound of claim 4 in a sample, the method comprising subjecting said sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy.

52. (new) A diagnostic kit for detecting the presence of campylobacter in animals or humans, said kit comprising the compound defined in claim 1.

53. (new) A diagnostic kit for detecting the presence of campylobacter in animals or humans, said kit comprising the compound defined in claim 4.